The press release is telling us that multiple comp
Post# of 72440
(Total Views: 216)
Posted On: 12/18/2017 10:33:00 AM
The press release is telling us that multiple companies are in serious talks. But it also tells us something else:
They're going to be able to formulate Brilacidin in a form that does not have to be refrigerated, and does not have the expense of manufacturing and transport that liquid formulations involve. It is very expensive to transport pre-mixed liquids in glass bottles. A shelf-stable powder, in a packet, is much lighter when you're shipping to thousands of pharmacies, and it takes up much less room on the shelf. When you sell liquid drugs, you're selling lots of water. If the patient can have this on hand and mix it themselves, it's going to be much easier for them to keep it for use when needed, too. I don't know if Brilacidin-OM liquid has to be refrigerated, but once you open a bottle, it usually has to be refrigerated.
People mix up saline solutions from little packets, to use for sinus irrigation, all the time. It's really easy.
But here's something else we can read between the lines to see:
This is going to be so easy to manufacture and distribute, that the company can GO IT ALONE IF NECESSARY. When someone tells you "we're improving the way that we formulate this to make it easy for patients, and we're going to give it to them in little packets for Phase 3, as we talk to the FDA to see how fast we can get it approved," they are also saying to Big Pharma: this is a unique drug with no competition, and it's going to be easy and inexpensive to manufacture. Pay up or we'll do it ourselves.
How hard to you think it would be to send email press releases to every board-certified oncologist, and every oncology practice and radiation facility in the U.S., announcing that this was approved and available?
Yep, not very hard, and not expensive to do.
Big Pharma spends a lot of money hiring reps to go out and give doctors free samples, gifts, golfing trips disguised as medical conventions, to get the doctors to prescribe their drug instead of a competing drug.
IPIX wouldn't have to do that. The drug really will sell itself, once oncologists and patients are aware of it.
A few TV ads like those Keytruda ads, telling patients they may be worried about side effects but now there's a drug that can help -- patients will clamor for it.
They're going to be able to formulate Brilacidin in a form that does not have to be refrigerated, and does not have the expense of manufacturing and transport that liquid formulations involve. It is very expensive to transport pre-mixed liquids in glass bottles. A shelf-stable powder, in a packet, is much lighter when you're shipping to thousands of pharmacies, and it takes up much less room on the shelf. When you sell liquid drugs, you're selling lots of water. If the patient can have this on hand and mix it themselves, it's going to be much easier for them to keep it for use when needed, too. I don't know if Brilacidin-OM liquid has to be refrigerated, but once you open a bottle, it usually has to be refrigerated.
People mix up saline solutions from little packets, to use for sinus irrigation, all the time. It's really easy.
But here's something else we can read between the lines to see:
This is going to be so easy to manufacture and distribute, that the company can GO IT ALONE IF NECESSARY. When someone tells you "we're improving the way that we formulate this to make it easy for patients, and we're going to give it to them in little packets for Phase 3, as we talk to the FDA to see how fast we can get it approved," they are also saying to Big Pharma: this is a unique drug with no competition, and it's going to be easy and inexpensive to manufacture. Pay up or we'll do it ourselves.
How hard to you think it would be to send email press releases to every board-certified oncologist, and every oncology practice and radiation facility in the U.S., announcing that this was approved and available?
Yep, not very hard, and not expensive to do.
Big Pharma spends a lot of money hiring reps to go out and give doctors free samples, gifts, golfing trips disguised as medical conventions, to get the doctors to prescribe their drug instead of a competing drug.
IPIX wouldn't have to do that. The drug really will sell itself, once oncologists and patients are aware of it.
A few TV ads like those Keytruda ads, telling patients they may be worried about side effects but now there's a drug that can help -- patients will clamor for it.
(10)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼